Top

Published in:

01-04-2014 | Original Article

microRNA expression might predict prognosis of epithelial hepatoblastoma

Authors: Mónika Gyugos, Gábor Lendvai, István Kenessey, Krisztina Schlachter, Judit Halász, Péter Nagy, Miklós Garami, Zsuzsa Jakab, Zsuzsa Schaff, András Kiss

Published in: Virchows Archiv | Issue 4/2014

Abstract

Hepatoblastoma (HB) is the most common primary liver cancer in childhood. The fetal and mixed embryonal/fetal epithelial subtypes of HB differ not only in grade of differentiation but probably also in prognosis. We aimed to determine microRNA (miRNA) expression patterns of the main subtypes of epithelial HBs to reveal differences and relate them to survival. We studied 20 cases of epithelial HB, subtyped as pure fetal (n = 12) or embryonal/fetal (n = 8). Tissues were sampled according to subtype to arrive at 15 purely fetal and eight purely embryonal samples (n = 8) and 15 samples of non-tumorous surrounding liver (SL). Relative expression of miR-17-5p, miR-18a, miR-21, miR-34a, miR-96, miR-122, miR-181a, miR-195, miR-210, miR-214, miR-221, miR-222, miR-223, and miR-224 was determined by TaqMan MicroRNA Assays applying miR-140 as reference. A higher level of miR-18a (p < 0.01) was found in embryonal samples than in fetal samples. Lower miR-17-5p, miR-195, miR-210, miR-214, and higher miR-221 levels were detected in fetal samples (p < 0.02) in comparison with SL samples, whereas a lower miR-122 level was observed in embryonal samples (p < 0.003). Histological subtype did not correlate with survival; however, high miR-21, low miR-222, and low miR-224 levels proved to be independently prognostic for HB with significantly increased overall survival (p < 0.03). The fetal and embryonal components of epithelial HB, as well as SL, revealed different miRNA expression patterns. Furthermore, miR-21, miR-222, and miR-224 levels predict overall survival of HB patients regardless of epithelial subtype.

Agarwala S (2012) Primary malignant liver tumors in children. Indian J Pediatr 79:793–800PubMedCrossRef

Lopez-Terrada D, Zimmermann A (2012) Current issues and controversies in the classification of pediatric hepatocellular tumors. Pediatr Blood Cancer 59:780–784PubMedCrossRef

Allan BJ, Parikh PP, Diaz S, Perez EA, Neville HL, Sola JE (2013) Predictors of survival and incidence of hepatoblastoma in the paediatric population. HPB (Oxford) 15:741–746CrossRef

Purcell R, Childs M, Maibach R, Miles C, Turner C, Zimmermann A, Sullivan M (2011) HGF/c-Met related activation of beta-catenin in hepatoblastoma. J Exp Clin Cancer Res 30:96PubMedCentralPubMedCrossRef

Dezso K, Halasz J, Bisgaard HC, Paku S, Turanyi E, Schaff Z, Nagy P (2008) Delta-like protein (DLK) is a novel immunohistochemical marker for human hepatoblastomas. Virchows Arch 452:443–448PubMedCrossRef

Halasz J, Holczbauer A, Paska C, Kovacs M, Benyo G, Verebely T, Schaff Z, Kiss A (2006) Claudin-1 and claudin-2 differentiate fetal and embryonal components in human hepatoblastoma. Hum Pathol 37:555–561PubMedCrossRef

Purcell R, Childs M, Maibach R, Miles C, Turner C, Zimmermann A, Czauderna P, Sullivan M (2012) Potential biomarkers for hepatoblastoma: results from the SIOPEL-3 study. Eur J Cancer 48:1853–1859PubMedCrossRef

Kiss A, Szepesi A, Lotz G, Nagy P, Schaff Z (1998) Expression of transforming growth factor-alpha in hepatoblastoma. Cancer 83:690–697PubMedCrossRef

Adesina AM, Lopez-Terrada D, Wong KK, Gunaratne P, Nguyen Y, Pulliam J, Margolin J, Finegold MJ (2009) Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. Hum Pathol 40:843–853PubMedCentralPubMedCrossRef

10.

Cairo S, Armengol C, Buendia MA (2012) Activation of Wnt and Myc signaling in hepatoblastoma. Front Biosci (Elite Ed) 4:480–486CrossRef

11.

Ciesla M, Skrzypek K, Kozakowska M, Loboda A, Jozkowicz A, Dulak J (2011) MicroRNAs as biomarkers of disease onset. Anal Bioanal Chem 401:2051–2061PubMedCrossRef

12.

Farazi TA, Spitzer JI, Morozov P, Tuschl T (2011) miRNAs in human cancer. J Pathol 223:102–115PubMedCentralPubMedCrossRef

13.

Braconi C, Henry JC, Kogure T, Schmittgen T, Patel T (2011) The role of microRNAs in human liver cancers. Semin Oncol 38:752–763PubMedCentralPubMedCrossRef

14.

Cairo S, Wang Y, de Reynies A, Duroure K, Dahan J, Redon MJ, Fabre M, McClelland M, Wang XW, Croce CM, Buendia MA (2010) Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. Proc Natl Acad Sci U S A 107:20471–20476PubMedCentralPubMedCrossRef

15.

Kerr TA, Korenblat KM, Davidson NO (2011) MicroRNAs and liver disease. Transl Res 157:241–252PubMedCentralPubMed

16.

Lakner AM, Bonkovsky HL, Schrum LW (2011) microRNAs: fad or future of liver disease. World J Gastroenterol 17:2536–2542PubMedCentralPubMedCrossRef

17.

Rong M, Chen G, Dang Y (2013) Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro. BMC Cancer 13:21PubMedCentralPubMedCrossRef

18.

Magrelli A, Azzalin G, Salvatore M, Viganotti M, Tosto F, Colombo T, Devito R, Di Masi A, Antoccia A, Lorenzetti S, Maranghi F, Mantovani A, Tanzarella C, Macino G, Taruscio D (2009) Altered microRNA expression patterns in hepatoblastoma patients. Transl Oncol 2:157–163PubMedCentralPubMedCrossRef

19.

Haas JE, Feusner JH, Finegold MJ (2001) Small cell undifferentiated histology in hepatoblastoma may be unfavorable. Cancer 92:3130–3134PubMedCrossRef

20.

Perilongo G, Malogolowkin M, Feusner J (2012) Hepatoblastoma clinical research: lessons learned and future challenges. Pediatr Blood Cancer 59:818–821PubMedCrossRef

21.

Perilongo G, Shafford E, Maibach R, Aronson D, Brugieres L, Brock P, Childs M, Czauderna P, MacKinlay G, Otte JB, Pritchard J, Rondelli R, Scopinaro M, Staalman C, Plaschkes J (2004) Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the international society of paediatric oncology—SIOPEL 2. Eur J Cancer 40:411–421PubMedCrossRef

22.

Doleshal M, Magotra AA, Choudhury B, Cannon BD, Labourier E, Szafranska AE (2008) Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues. J Mol Diagn 10:203–211PubMedCentralPubMedCrossRef

23.

Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D (2013) Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog 52:297–303PubMedCrossRef

24.

Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP, Odenthal M (2008) MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 47:1223–1232PubMedCrossRef

25.

Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM, Dejean A (2010) miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A 107:264–269PubMedCentralPubMedCrossRef

26.

Andersen CL, Jensen JL, Orntoft TF (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64:5245–5250PubMedCrossRef

27.

Ismail H, Broniszczak D, Kalicinski P, Dembowska-Baginska B, Perek D, Teisseyre J, Kluge P, Kosciesza A, Lembas A, Markiewicz M (2012) Changing treatment and outcome of children with hepatoblastoma: analysis of a single center experience over the last 20 years. J Pediatr Surg 47:1331–1339PubMedCrossRef

28.

Shenouda SK, Alahari SK (2009) MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev 28:369–378PubMedCrossRef

29.

Lopez-Terrada D, Gunaratne PH, Adesina AM, Pulliam J, Hoang DM, Nguyen Y, Mistretta TA, Margolin J, Finegold MJ (2009) Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK + precursors. Hum Pathol 40:783–794PubMedCrossRef

30.

Chopra A, Iyer VK, Agarwala S, Mathur SR, Aron M, Gupta SD, Verma K (2010) Apoptotic protein expression, glycogen content, DNA ploidy and cell proliferation in hepatoblastoma subtyping and their role in prognostication. Pediatr Surg Int 26:1173–1178PubMedCrossRef

31.

von Frowein J, Pagel P, Kappler R, von Schweinitz D, Roscher A, Schmid I (2011) MicroRNA-492 is processed from the keratin 19 gene and up-regulated in metastatic hepatoblastoma. Hepatology 53:833–842CrossRef

32.

Scisciani C, Vossio S, Guerrieri F, Schinzari V, De Iaco R, D’Onorio de Meo P, Cervello M, Montalto G, Pollicino T, Raimondo G, Levrero M, Pediconi N (2012) Transcriptional regulation of miR-224 upregulated in human HCCs by NFkappaB inflammatory pathways. J Hepatol 56:855–861PubMedCrossRef

33.

Boutz DR, Collins PJ, Suresh U, Lu M, Ramirez CM, Fernandez-Hernando C, Huang Y, Abreu Rde S, Le SY, Shapiro BA, Liu AM, Luk JM, Aldred SF, Trinklein ND, Marcotte EM, Penalva LO (2011) Two-tiered approach identifies a network of cancer and liver disease-related genes regulated by miR-122. J Biol Chem 286:18066–18078PubMedCentralPubMedCrossRef

34.

Hu J, Xu Y, Hao J, Wang S, Li C, Meng S (2012) MiR-122 in hepatic function and liver diseases. Protein Cell 3:364–371PubMedCrossRef

35.

Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM (2009) MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 50:113–121PubMedCrossRef

36.

Chen L, Jiang M, Yuan W, Tang H (2012) miR-17-5p as a novel prognostic marker for hepatocellular carcinoma. J Invest Surg 25:156–161PubMedCrossRef

37.

Yang W, Sun T, Cao J, Liu F, Tian Y, Zhu W (2012) Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro. Exp Cell Res 318:944–954PubMedCrossRef

38.

El Tayebi HM, Omar K, Hegy S, El Maghrabi M, El Brolosy M, Hosny KA, Esmat G, Abdelaziz AI (2013) Repression of miR-17-5p with elevated expression of E2F-1 and c-MYC in non-metastatic hepatocellular carcinoma and enhancement of cell growth upon reversing this expression pattern. Biochem Biophys Res Commun 434:421–427PubMedCrossRef

39.

Wang X, Chen J, Li F, Lin Y, Zhang X, Lv Z, Jiang J (2012) MiR-214 inhibits cell growth in hepatocellular carcinoma through suppression of beta-catenin. Biochem Biophys Res Commun 428:525–531PubMedCrossRef

40.

Wu W, Takanashi M, Borjigin N, Ohno SI, Fujita K, Hoshino S, Osaka Y, Tsuchida A, Kuroda M (2013) MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis. Br J Cancer 108:653–661PubMedCentralPubMedCrossRef

41.

Brock M, Trenkmann M, Gay RE, Gay S, Speich R, Huber LC (2011) MicroRNA-18a enhances the interleukin-6-mediated production of the acute-phase proteins fibrinogen and haptoglobin in human hepatocytes. J Biol Chem 286:40142–40150PubMedCentralPubMedCrossRef

42.

Wong QW, Ching AK, Chan AW, Choy KW, To KF, Lai PB, Wong N (2010) MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res 16:867–875PubMedCrossRef

43.

Garofalo M, Quintavalle C, Romano G, Croce CM, Condorelli G (2012) miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med 12:27–33PubMedCentralPubMedCrossRef

44.

Ma D, Tao X, Gao F, Fan C, Wu D (2012) miR-224 functions as an onco-miRNA in hepatocellular carcinoma cells by activating AKT signaling. Oncol Lett 4:483–488PubMedCentralPubMed

45.

Shen SN, Wang LF, Jia YF, Hao YQ, Zhang L, Wang H (2013) Upregulation of microRNA-224 is associated with aggressive progression and poor prognosis in human cervical cancer. Diagn Pathol 8:69PubMedCentralPubMedCrossRef

46.

Lu S, Wang S, Geng S, Ma S, Liang Z, Jiao B (2013) Upregulation of microRNA-224 confers a poor prognosis in glioma patients. Clin Transl Oncol 15:569–574PubMedCrossRef

47.

Zhu Q, Wang Z, Hu Y, Li J, Li X, Zhou L, Huang Y (2012) miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma. Oncol Rep 27:1660–1668PubMed

48.

Bao L, Yan Y, Xu C, Ji W, Shen S, Xu G, Zeng Y, Sun B, Qian H, Chen L, Wu M, Chen J, Su C (2013) MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. Cancer Lett 337:226–236PubMedCrossRef

Title: microRNA expression might predict prognosis of epithelial hepatoblastoma
Authors: Mónika Gyugos
Gábor Lendvai
István Kenessey
Krisztina Schlachter
Judit Halász
Péter Nagy
Miklós Garami
Zsuzsa Jakab
Zsuzsa Schaff
András Kiss
Publication date: 01-04-2014
Publisher: Springer Berlin Heidelberg
Published in: Virchows Archiv / Issue 4/2014
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-014-1549-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

microRNA expression might predict prognosis of epithelial hepatoblastoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

Lipomatous tumors of the anterior mediastinum with muscle differentiation: a clinicopathological and immunohistochemical study of three cases

Reproducibility of histopathologic tumor grading in penile cancer—results of a European project

Gastritis staging: interobserver agreement by applying OLGA and OLGIM systems

Clinicopathological and prognostic significance of EZH2 expression in upper urinary tract carcinoma

Retroperitoneal dedifferentiated liposarcoma lacking MDM2 amplification in a patient with a germ line CHEK2 mutation

In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor